BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget 2016;7:2734-53. [PMID: 26673621 DOI: 10.18632/oncotarget.6548] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res 2017;27:545-57. [PMID: 29076949 DOI: 10.1097/CMR.0000000000000403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Shin SY, Müller AK, Verma N, Lev S, Nguyen LK. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. PLoS Comput Biol 2018;14:e1006192. [PMID: 29920512 DOI: 10.1371/journal.pcbi.1006192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Roller DG, Hoang SA, Rawls KD, Owen KA, Simmers MB, Figler RA, Wulfkuhle JD, Petricoin EF, Wamhoff BR, Gioeli D. Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response. Sci Rep 2021;11:5535. [PMID: 33692370 DOI: 10.1038/s41598-021-84612-z] [Reference Citation Analysis]
4 Yaman S, Ramachandramoorthy H, Oter G, Zhukova D, Nguyen T, Sabnani MK, Weidanz JA, Nguyen KT. Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer. Front Bioeng Biotechnol 2020;8:943. [PMID: 32850765 DOI: 10.3389/fbioe.2020.00943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 2016;14:1019-29. [PMID: 27422710 DOI: 10.1158/1541-7786.MCR-15-0506] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
6 Pisanu ME, Maugeri-Saccà M, Fattore L, Bruschini S, De Vitis C, Tabbì E, Bellei B, Migliano E, Kovacs D, Camera E, Picardo M, Jakopin Z, Cippitelli C, Bartolazzi A, Raffa S, Torrisi MR, Fulciniti F, Ascierto PA, Ciliberto G, Mancini R. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. J Exp Clin Cancer Res 2018;37:318. [PMID: 30558661 DOI: 10.1186/s13046-018-0989-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
7 Song Q, Sun X, Guo H, Yu Q. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget 2017;8:5003-15. [PMID: 28002807 DOI: 10.18632/oncotarget.14009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Vidarsdottir L, Azimi A, Das I, Sigvaldadottir I, Suryo Rahmanto A, Petri A, Kauppinen S, Ingvar C, Jönsson G, Olsson H, Frostvik Stolt M, Tuominen R, Sangfelt O, Pokrovskaja Tamm K, Hansson J, Grandér D, Egyházi Brage S, Johnsson P. PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. Sci Rep 2021;11:11023. [PMID: 34040017 DOI: 10.1038/s41598-021-89389-9] [Reference Citation Analysis]
9 Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Cell Death Dis 2017;8:e3029. [PMID: 29048432 DOI: 10.1038/cddis.2017.406] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
10 Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL Jr, Abbas T. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine 2016;10:85-100. [PMID: 27333051 DOI: 10.1016/j.ebiom.2016.06.023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
11 Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, Michelini S, Volpe S, Mambrin A, Mangino G, Romeo G, Maddalena P, Rees C, Potenza C. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers (Basel) 2020;12:E2801. [PMID: 33003483 DOI: 10.3390/cancers12102801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Mol Carcinog 2017;56:1515-25. [PMID: 28052407 DOI: 10.1002/mc.22611] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]